Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Open-label, Single-center, Single-dose, Parallel Group Study to Evaluate the Pharmacokinetics of BV100 in Participants with Mild, Moderate, and Severe Hepatic Impairment Compared to Matched Healthy Control Participants

NCT05537142 is registered in ClinicalTrials.gov with BioVersys AG as lead sponsor.

NCT NCT05537142
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05537142 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Open-label, Single-center, Single-dose, Parallel Group Study to Evaluate the Pharmacokinetics of BV100 in Participants with Mild, Moderate, and Severe Hepatic Impairment Compared to Matched Healthy Control Participants
Lead sponsor
BioVersys AG
Phase
Phase 1
Overall status
Completed
Start date
September 2, 2022
Completion date
October 30, 2024
Enrollment
33 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy participants